News | July 22, 2023
Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Subscribe To Our Newsletter & Stay Updated
